Advancing Academic Discoveries in Neuroscience. Together.

The SPARK NS Translational Research Program eliminates barriers to success.

2 people collaborating in front of an orange line bending behind them going from left to right

Our vision

Every person with a neurological disorder has safe and effective treatments and cures.
Drug development is hard!

We fill gaps in knowledge and know-how

We bring academic researchers together to learn from their peers and industry experts and put aside competing interests for the benefit of patients.

OurProgram
A young latin woman showing an older asian woman information on her tablet with graphic stripes wrapping around them.
From Lab To Clinic

All the resources you need

Our program helps academic principal investigators advance therapeutic discoveries at any stage between target identification and entry into clinical trials.

OurProgram

Up to $2,000,0001 in milestone-based funding

Advice from 90+ industry expert advisors

In-person and online education in drug development

Participation in a collaborative community

Post-program support

PROVEN RESULTS

A model that works

The SPARK NS program uses a translational research model with an unprecedented 50%3 success rate developed, refined, and used since 2006.

OurProgram
A black and white illustration of a brain
Source: Cajal, 1899
Learn More

The SPARK NS Translational Research Program

SPARK NS is no longer accepting applications for the 2027 Cohort of our translational research program. Finalists will be notified in September 2026 with finalist presentations to be held in October 2026. We will release an open Call for Proposals for the 2028 Cohort in the spring of 2027.

Learn More
  1. Not all funds awarded go directly to PIs’ laboratories. For example, work done by contract research organizations or academic research facilities will be paid for by SPARK NS directly to the organizations from awarded funds.

  2. Kim, J.S., Kargotich, S., Lee, S.H. et al. SPARKing academic technologies across the valley of death. Nature Biotechnology 42, 339–342 (2024).